Waaree Energies — India's vertically integrating solar OEM

1. Snapshot

Waaree Energies sits at the equipment / OEM node of the Indian solar value chain — it makes the panels, increasingly the cells behind them, and is bolting on everything else (wafers, glass, inverters, batteries, even electrolysers). It is the largest non-Chinese solar module manufacturer in the world, with ~26 GW of module capacity and 5.4 GW of cell capacity. Listed October 2024, it now trades at ₹3,125 (market cap ₹89,903 Cr), in a 52-week band of ₹2,402–3,865, on a P/E of 22.9 and a punchy ROE of 32.8% / ROCE of 38.8%. The animal: a fast-growing, capex-hungry manufacturing cyclical riding a policy-protected domestic boom and a tariff-arbitraged US export window — priced more like a compounder than a commodity OEM. As of 2026-06-20, from screener snapshot.

2. Business & position in the value chain

Waaree is a manufacturer first, integrator increasingly, developer at the edges. The core is solar PV modules — it produced 12.6 GW and sold ~12 GW in FY26, roughly 56,000 panels a day. Around that core sit four concentric layers:

• Module (the cash engine): ~26 GW of nameplate across five Indian plants plus a US plant in Houston. Bread and butter.
• Cells (the integration play): 5.4 GW operational — India’s largest single cell facility — with a 10 GW cell expansion going live in H2 FY26, taking cell capacity to ~15.5 GW, enough to feed its own module lines.
• Upstream beyond cells (the moat-deepening): a 10 GW ingot-wafer plant under construction at Nagpur (₹6,200 Cr, now FY28), a ₹3,900 Cr PV-glass plant (2,500 TPD — glass is ~20% of module cost, 75% of module weight), and a strategic stake in United Polysilicon (Oman) to lock in traceable non-Chinese polysilicon.
• Adjacencies (the “Waaree 2.0” sprawl): 20 GWh of battery storage (BESS, ₹10,000 Cr), 4 GW inverters, 20,000 MVA transformers, a 1 GW green-hydrogen electrolyser line, a developer/IPP arm (713 MW of signed PPAs, ~8 GW connectivity secured), an EPC business (5+ GW executed), and an entry into T&D via the 55% APSL acquisition (₹1,225 Cr).

Revenue mix in FY26 was deliberately spread: Utility/IPP/C&I 34.7%, Overseas 33%, Retail 20.8%, EPC 11.6%. The standout is retail — ₹5,515 Cr, up 84%, “one in six installations in India carries the Waaree name,” across 27 states and 600+ franchises. That B2C distribution engine is the genuinely hard-to-copy asset; the rest is capital and execution.

Concentration to watch: ~33% of revenue is overseas, the bulk of it US-bound. The ₹53,000 Cr order book is 65–70% overseas, deliverable over 3–4 years — so a large, lumpy slug of the visible book rides on US policy holding.

3. Management & promoter quality

The promoters are the Doshi family — Hitesh, Viren, and Pankaj Chimanlal Doshi plus the family holding vehicle — who hold 64.19%, down a whisker from 64.31% at listing (screener). Promoter holding has been essentially flat post-IPO — no creeping OFS dribble, which is a small positive in a sector where promoters often monetise into euphoria.

The governance texture is mixed-to-good:

• Restructuring for clarity: In 2025 the family dissolved four HUFs to consolidate ownership under individual promoters — read as succession/governance tidying rather than a flag (HDFC Sky). A promoter also transferred 200,000 shares (~0.07%) to charitable trusts in June 2026 (scanx).
• Capital allocation — the central judgment call: This is a “plough everything back” management. Dividend payout is ~2% (effectively zero), and the company is committing $3.5 billion (₹30,000 Cr) of capex over two years across a dozen verticals. They frame it as “book and build” — capex backed by confirmed demand — and point to a decade of debt-to-equity below 1.0 despite heavy capex. The delivery record backs the swagger: FY26 reported EBITDA of ₹6,617 Cr beat their own ₹5,500–6,000 Cr guidance, and the US plant went greenfield-to-running in 12 months. That is real execution.
• The honest worry: the breadth. A focused module-and-cell champion is being turned into an “everything in the energy transition” conglomerate — electrolysers, transformers, semiconductors (the new Waaree Semicon diode entity), hydrogen. Each is defensible as an adjacency; together they are a lot of simultaneous learning curves funded partly by a proposed ₹10,000 Cr fresh raise (enabling resolution passed). Management’s record buys them benefit of the doubt; the next two capex-heavy years are where the doubt gets tested.

No pledging or related-party drama has surfaced. FIIs have moved in (1.4% → 7.06% over FY25–26), DIIs to 4.32% — institutions are warming, not fleeing.

4. Financial trends

For an OEM, the right lens is order book × execution × working capital × margin durability — and on the first three Waaree screens beautifully; the fourth is the live debate.

Metric	FY24	FY25	FY26
Revenue (₹ Cr)	11,398	14,444	26,537
OPM %	14%	19%	22%
Net Profit (₹ Cr)	1,274	1,928	3,884
EPS (₹)	62.8	65.0	129.0
ROCE %	44%	35%	39%
CFO/OP %	168%	143%	47%
Debt (₹ Cr)	553	1,199	3,213

• Growth: revenue 84% YoY in FY26, PAT +101%; 5-yr PAT CAGR ~143%. Accelerating, not stalling — though off a base inflated by an unusually generous DCR-pricing window.
• Margins: OPM has climbed 4% → 22% over five years as the mix shifted to higher-value DCR/cell-integrated panels and exports. But Q4 FY26 OPM fell to 19% from 25% — a ~590 bps drop management blamed on silver/copper spikes, freight, lower export mix, and having to buy in cells to meet DCR orders. This is the cyclicality tell: margins here are a function of commodity prices, sales mix, and the DCR/non-DCR spread, none of which Waaree fully controls yet.
• Returns: ROE 32.8%, ROCE 38.8% — genuinely high, driven by operating quality rather than leverage. The screener pros (“good ROE track record,” “143% profit CAGR”) are accurate but backward-looking; they describe a window of policy-protected super-normal returns, not a steady state.
• Balance sheet: D/E still comfortably under 1 (₹3,213 Cr debt vs ₹14,438 Cr net worth). Capex is the strain, not leverage — yet.
• Cash flow — the one real yellow flag: CFO/OP collapsed to 47% (from 143%+) and FCF was −₹3,209 Cr in FY26. Management attributes it to a Q4 inventory build-up from stranded export shipments (Middle East logistics) that should reverse. Plausible, and the balance-sheet inventory bulge supports the story — but at this capex intensity, cash conversion is the number to keep honest. Cash conversion cycle stretched to 90 days from 35.

5. Latest quarter

Q4 FY26, reported 29 Apr 2026; concall 30 Apr 2026. Revenue ₹8,480 Cr (+111% YoY), PAT ₹1,126 Cr (+75%), but EBITDA margin compressed to ~19%. CEO Jignesh Rathod called FY26 “a year of record-breaking performance”; the friction was all in the margin line.

Management was candid on the squeeze: “Over the last quarter, we have seen two things which no one envisaged — the war in the Middle East and the crisis of commodity prices… the biggest impact was silver pricing and copper pricing,” compounded by freight and a lower export mix. Crucially, they flagged a structural margin reset down: asked point-blank, CFO Abhishek Pareek guided to “19%-20% margin consistent for a decade long at least” — well below the 23–25% prints of late FY26. The offset is integration: once the 10 GW cell plant runs in H2, “our entire requirement of cells for the Indian market [will] be manufactured and sourced in-house,” lifting the DCR margin capture.

Guidance: FY27 operating EBITDA of ₹7,000–7,700 Cr (~20–25% growth on FY26’s ₹5,909 Cr) (scanx). They were explicit that this number already absorbs pre-startup costs of plants going live this year — i.e., FY27 is a transition year, with the “Waaree 2.0” payoff weighted to H2 FY26 onward and a step-change in FY28–29.

6. What’s happening now

The live wires, tagged HARD (done/commissioned) vs SOFT (announced/under-construction):

• HARD — US tariff insulation: the 1.6 GW Houston plant is ramped; capacity scaling to 4.2 GW over six months to serve US demand locally, side-stepping the preliminary 126% US countervailing duty on Indian solar (final ruling ~July 2026) (Deccan Herald; Tradebrains). For India-to-US exports it routes cells through Ethiopia (~10% duty) vs Indonesia (~44%) to manage origin rules.
• HARD — FEOC tailwind: from April 2026, all components into the US (glass, EVA, backsheet, junction box — not just cells) must be non-Chinese (FEOC-compliant), which management calls “an enabling factor for non-Chinese players” — it’s generating new US order inflow and gives the planned PV-glass plant captive offtake from day one.
• HARD — ALMM List-II & DCR tailwind (domestic): from June 1, 2026, projects must use ALMM List-II domestic cells, collapsing “effective supply” from ~160 GW of modules to ~30 GW of integrated cell+module capacity. DCR modules carry a ₹8–10/W premium (SolarQuarter; TaiyangNews). Waaree’s cell ramp is timed to harvest exactly this.
• HARD/SOFT — backward & horizontal integration: Oman polysilicon stake (done); Nagpur 10 GW ingot-wafer under construction (FY28); 2,500 TPD PV glass approved (~24 months); 3.5 GWh of the 20 GWh BESS due this year; 4 GW inverters (3 GW commissioned); 1 GW electrolyser with ₹444 Cr electrolyser PLI + ₹510 Cr hydrogen PLI secured.
• SOFT — T&D entry: 55% of APSL (₹1,225 Cr) via WRTL; a new T&D EPC adjacency.
• SOFT — ₹10,000 Cr fundraise: enabling resolution passed, to fund the platform build-out.

Tie to the sector: this is the PLI + ALMM + FEOC trifecta working in Waaree’s favour — protected domestic demand and a tariff-walled US window — set against the global backdrop of Chinese oversupply (Chinese makers lost ~$5.5 bn in 2025) that keeps non-protected module prices structurally weak (SaurEnergy).

7. Expectations baked in

At ₹3,125 the market pays ~22.9x trailing earnings for a business that doubled profit and is guiding ~20–25% EBITDA growth into FY27. On the face of it that PEG looks undemanding — and Waaree screens cheaper than peer Premier Energies (~32–34x) on both trailing and FY27E earnings, partly because Waaree’s big capacity slug hits sooner (Whalesbook).

But the multiple is doing quiet work. A reverse-DCF feel: ~23x on a 30%+ ROE manufacturer implies the market expects (a) today’s super-normal margins to persist long enough to compound through the ₹30,000 Cr capex, and (b) the US window and DCR premium to stay open. Management itself has guided margins down to 19–20% steady-state — so part of the “cheap” trailing P/E is flattered by a peak-margin year. Normalise EBITDA margin toward 20% and grow volumes, and the multiple is fair-to-full rather than a bargain.

In short: the price is paying for a policy-protected growth compounder, not a commodity OEM. That is the correct read of today’s Waaree — but it bakes in continuity of three things (US local-content tailwind, ALMM/DCR pricing, and flawless multi-vertical execution) that are individually likely and jointly fragile.

8. Rerating signals — up vs down

Could re-rate UP if…	Could re-rate DOWN if…
10 GW cell plant ramps on time in H2 FY26 and self-sourced cells lift DCR margin capture, validating the integration thesis	US issues an adverse final tariff/FEOC ruling (July 2026) or rules change, impairing the 65–70% overseas order book
FY27 EBITDA lands at/above the ₹7,000–7,700 Cr guide, proving the margin reset (19–20%) is a floor, not a slide	Module-price cyclicality + Chinese oversupply bleeds into protected markets; non-DCR/export realisations crack
Cash conversion normalises (CFO/OP back to 70–100%) as the inventory bulge unwinds, easing the FCF worry	Cash conversion stays weak and the ₹30,000 Cr capex forces the ₹10,000 Cr raise to grow into heavier debt/dilution
Backward integration (wafer, glass, polysilicon) structurally lowers cost and steadies margins through the cycle	DCR/ALMM premium compresses as domestic cell capacity floods in by FY28 (ALMM-III), eroding the scarcity rent
Adjacencies (BESS, inverters, electrolysers) convert from capex to cash and earn the “energy-transition platform” multiple	Execution slips on one or more of a dozen simultaneous new verticals; the conglomerate sprawl drags ROCE
Retail B2C engine keeps compounding 80%+ as a low-capex, sticky, margin-rich annuity	Promoter dilution accelerates, or governance friction surfaces from the rapid corporate-structure proliferation

9. Conviction texture

The bull case is clean and almost elegant: Waaree is the largest non-Chinese module maker on earth, sitting at the exact intersection of two policy walls — India’s ALMM/DCR domestic-content regime and America’s FEOC/anti-China content rules — that together create a protected pricing pocket no Chinese giant can enter. It is integrating backward fast enough to own its own cost curve, it has the only genuine retail distribution moat in Indian solar, and the management has delivered: beat guidance, built a US plant in a year, kept leverage under control through a brutal capex cycle. At ~23x with 30%+ returns and 80% growth, you are arguably not overpaying for that.

The bear case is equally coherent: this is a manufacturing cyclical in fancy dress. The returns are real but rented — rented from a DCR premium that exists only because domestic cell supply is temporarily short, and from a US window that exists only at the pleasure of a tariff regime up for final ruling in weeks. Management itself told you margins reset down to 19–20%. FCF was negative ₹3,200 Cr and cash conversion fell to 47% in the very year profits doubled. And the answer to all of it is to spend $3.5 billion building a dozen new businesses at once — wafers, glass, batteries, hydrogen, transformers, even semiconductors — funded partly by fresh equity. When the policy scarcity normalises (ALMM-III, more domestic cell capacity by FY28, Chinese oversupply pressing on every unprotected watt), the question is whether the integration has bought a durable cost moat or just a bigger, more capital-hungry cyclical.

What the data actually supports: the growth and the execution are not in doubt — the order book, the production ramp, the guidance beat are all hard. What is genuinely uncertain is margin durability and cash conversion through a capex cycle whose payoff is weighted to FY28–29. The screener pros are true and the concall is confident, but both describe the up-leg of a protected window. To know which way this breaks, watch three numbers each quarter, exactly as the CFO suggested: DCR cells made-and-shipped in-house, overseas revenue mix, and CFO/OP conversion — plus the July US ruling. Get those right and the integration thesis carries it; get the policy or the cash wrong and the multiple has further to fall than the earnings.